Skip to main content

Drug Interactions between allopurinol / lesinurad and Videx

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

allopurinol didanosine

Applies to: allopurinol / lesinurad and Videx (didanosine)

CONTRAINDICATED: Coadministration with allopurinol may significantly increase the plasma concentrations of didanosine. The proposed mechanism is allopurinol inhibition of didanosine first-pass metabolism via xanthine oxidase. In two patients with renal impairment (CrCl = 15 and 18 mL/min), allopurinol (300 mg/day) increased the area under the plasma concentration-time curve (AUC) of didanosine (200 mg single dose) by approximately 4-fold. In fourteen healthy volunteers, the mean AUC of didanosine (400 mg single dose) was increased about 2-fold by allopurinol (300 mg/day for 7 days). In one study, four patients treated with an antiretroviral regimen containing didanosine (four 100 mg chewable tablets/day) were able to maintain similar didanosine plasma levels and antiretroviral competency with half the dosage of didanosine during coadministration with allopurinol (300 mg/day). These effects persisted after several months of concomitant treatment.

MANAGEMENT: Because elevated plasma levels of didanosine may be associated with increased risk of serious adverse effects such as pancreatitis and peripheral neuropathy, as well as increased serum uric acid concentrations, the concomitant use of didanosine and allopurinol is considered contraindicated.

References

  1. (2002) "Product Information. Videx (didanosine)." Bristol-Myers Squibb
  2. Boelaert JR, Dom GM, Huitema AD, Beijnen JH, Lange JM (2002) "The boosting of didanosine by allopurinol permits a halving of the didanosine dosage." AIDS, 16, p. 2221-2223

Switch to consumer interaction data

Drug and food interactions

Moderate

didanosine food

Applies to: Videx (didanosine)

ADJUST DOSING INTERVAL: Didanosine bioavailability is decreased when administered with food. Loss of efficacy may result.

MANAGEMENT: Didanosine should be administered in the fasting state, at least 30 minutes before or more than 2 hours after eating.

References

  1. (2002) "Product Information. Videx (didanosine)." Bristol-Myers Squibb

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer